Record order book, margin recovery roadmap credible but Q1 soft
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Executing capex milestones (3 GW module, 10 GW cell on-track, APS deal closed), but Q1 margins compressed; FY27 target requires H2 acceleration.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Structural thesis intact: ₹61,500 Cr order book, cell capacity scaling to 15.4 GW, retail doubling to ₹10K Cr/yr, vertical integration deepening. But Q1 delivered softer margins (18.1% OPM, PAT +15% vs revenue +79%), module production fell QoQ, and FY27 ₹7,000-7,700 Cr EBITDA guidance reaffirmed (not raised) looks ambitious at current run-rate.
₹7932 Cr
Revenue · +79.2% YoY₹892 Cr
Reported PAT · +15.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Highest order book ₹61,500 Cr, up from ₹50,000 Cr last quarter
METConfirmed; order book composition well-diversified (40% India, 36% US, 24% exports)
Revenue grew 79.2% YoY to ₹7,932 Cr
METDelivered ₹7,931.8 Cr; exact match to guidance
Operating EBITDA ₹1,440 Cr at 18.2% margin, up 44.4% YoY
METDelivered OPM 18.1% (marginally lower); EBITDA growth rate not separately verifiable but plausible
Retail revenue up 130% YoY from ₹995 Cr to ₹2,289 Cr
METConfirmed; targeting ₹9,000-10,000 Cr FY27 implies ₹2,250-2,500 Cr average Q2-Q4
Module volumes up 89% YoY from 1.9 GW to 3.6 GW
OVERSTATEDBut production fell from 4.2 GW last quarter to 3.6 GW this quarter (–14% QoQ). YoY growth narrative masks QoQ decline
FY27 EBITDA guidance ₹7,000-7,700 Cr reaffirmed; cell ramp-up backs margin recovery
CorroboratedQ1 EBITDA ₹1,440 Cr implies ₹5,560-6,260 Cr needed Q2-Q4 (avg ₹1,853-2,087 Cr/Q). Cell production 800 MW→1.5 GW trajectory credible but ambitious
Earnings quality
What changed since the last call
Guidance reaffirmed, not raised
NeutralFY27 EBITDA target ₹7,000-7,700 Cr held vs prior call; no numeric upgrade despite record order book. Q1 EBITDA only ₹1,440 Cr suggests H2 needs acceleration.
Retail business doubling fast
UpgradeRetail revenue ₹2,289 Cr this Q, +130% YoY (vs ₹995 Cr prior year). Management now confident on ₹9,000-10,000 Cr FY27 target, unlocking consumer channel.
U.S. tariff headwinds real
DowngradeExport revenue softer; clearance delays cited. Varun noted 6-month market lull due to tariff confusion. Recovery assumed Q2 onwards but not certain.
Capex execution visible but capex-heavy
Neutral₹31,500 Cr total capex approved; ₹9,450 Cr deployed (30% of FY27 budget). Cell, inverter, T&D, BESS all live or near-live; but execution risk on timing & ROE remains.
Cell integration roadmap crystallizing
Upgrade10 GW cell capacity fully equipped, ALMM-II applied. Cell-to-module ratio to jump from 20% to 65%, directly supporting margin recovery thesis from Q3 onwards.
The Q&A
Analysts pressed on U.S. export collapse (Kunal Shah, DAM), margin profile (Sweta Jain, Anand Rathi), and ALMM/DCR dependency (Venkatesha RJ). Management held up well, providing transparent cell pricing ($0.07-0.08/Wp mfg vs $0.12-0.13/Wp DCR market), IRA detail ($0.07/Wp plus expenses), and 10-year pre-policy track record (20% CAGR). Hedged on segment-margin guidance but provided operational specifics.
Expansion capex sequencing — Vishal, ValueQuest
PartialCell equipment on-site, expected live Q3 FY27. FY28 will see 10 GW cell at full run, module 16-18 GW, EBITDA significantly higher. Exact FY28 numbers not guided.
Module margin decline — Vishal, ValueQuest
AnsweredFour levers: (1) DCR cell production rising (800 MW→1.5 GW); (2) U.S. local production + IRA ($0.07/Wp); (3) exports restarting Aug; (4) non-DCR offtake window opening. By Dec, 10 GW cell goes live, completing India integration.
U.S. export tariff risk — Kunal Shah, DAM Capital
Answered6-month market lull ended; new supply chains tapped; U.S. local 1.6 GW capacity ramping. U.S. order book 25% of total, will ship from local facility, not export.
U.S. manufacturing profitability — Sweta Jain, Anand Rathi
PartialExport ≈$0.04-0.05/Wp EBITDA. U.S. local ≈$0.07-0.08/Wp (includes IRA $0.07, less $0.01-0.02 conversion cost as capacity scales). Retail margin not detailed.
Cell pricing & competitiveness — Praveen Sahay, PL Capital
AnsweredImport $0.04-0.045/Wp. Local mfg cost $0.07-0.08/Wp. DCR market price $0.12-0.13/Wp. Clear margin opportunity.
BESS business outlook & orders — Sabri Hazarika, Emkay Global
Partial5.15 GWh container live. 3.5 GWh cell + 5.15 GWh pack ramping. Already have 1,500 MWh EPC order. FEOC-compliant cells premium 25-30% vs China. Markets: India utility, retail, U.S./Europe FEOC, Australia NZ.
QIP capital raise strategy — Suyash Kela, Singularity AMC
PartialBoard approval for ₹10,000 Cr. Current cash ₹7,000 Cr. Own EBITDA guidance sufficient for capex, but QIP will strengthen balance sheet. Waiting for right market window.
Module capacity utilization path — Nirmal, Aditya Birla Sun Life
PartialHistorical utilization 70-75%; expect same with more cell integration. With cell capacity coming up Q3-Q4, offtake expected to rise to 80-85% utilization.
IRA incentive cash flow timing — Prakhar Porwal, Ambit Capital
AnsweredTwo options: file tax return for refund, or sell incentive. Already in discussion with large U.S. players. Can assume cash starting Q3-Q4 on quarterly accrual basis.
China competitiveness post-tariffs — Venkatesha RJ, independent analyst
AnsweredVarun: 10-year track record shows 20% CAGR pre-policy. India cost gap only $0.025-0.03/Wp vs China. Policies (ALMM, PLI) are structural (like defence, electronics), not temporary. FY29 onwards entire India DCR; wafer policy June '28. India becomes self-reliant.
Margin expansion from cell+wafer integration — Nitin Kaushik, Afin Capital
AnsweredModule-only suppliers ≈20-25% margin. Module+cell integrated ≈35-41% margin. No segment-specific guide, but range is clear.
Solar glass capex strategy — Kaushal Sharma, Equinox Capital
PartialBoard approved greenfield. Open to various channels for supply security. Glass is 2nd-largest element in module value. Update expected next quarter on capex + supply chain.
BESS capex and contract visibility — Sumit Kishore, Axis Capital
Partial3.5 GWh cell + 5.15 GWh pack+container 95% ready. 1,500 MWh EPC order alone covers full year production. FEOC-compliant cells 25-30% premium. Two markets: India solution + retail; global FEOC cell (Make in India for export).
Guidance
FY27 retail revenue ₹9,000-10,000 Cr (vs ₹995 Cr FY26)
HighQ1 retail at run-rate ₹2,289 Cr annualizes to ₹9.2 Cr; franchise network deepening, e-commerce scaling, government rooftop schemes (PM Surya Ghar) tailwinds.
Operating EBITDA FY27 ₹7,000-7,700 Cr (reaffirmed from prior call)
MediumQ1 EBITDA ₹1,440 Cr implies ₹5,560-6,260 Cr Q2-Q4; avg ₹1,853-2,087 Cr/Q needed. Cell ramp (800 MW→1.5 GW), margin lever (+35-41% cell-integrated vs 20-25% module-only) and capacity utilization (50%→75%+) cited as recovery mechanisms; ambitious but achievable if execution flawless.
Total capex ₹31,500 Cr over 3 years: 30% FY27, 40% FY28, 30% FY29
High₹9,450 Cr deployed by Jun 2026. FY27 focus: 2.6 GW module (Waaree Americas), 10 GW cell (India), 20 GVA transformer, 4 GW inverter, 1 GW electrolyzer. Milestone-gated, ROCE-accretive, backed by order visibility.
Risks the call surfaced
U.S. tariff & trade
HighU.S. export revenue fell sharply Q1; management blamed 6-month tariff-induced lull. Recovery assumed Q2+ but not guaranteed. 25% of order book is U.S. exports; if tariffs widen, margin on $0.04-0.05/Wp exports erodes faster than domestic DCR.
Cell capacity ramp execution
High10 GW cell capacity expected online by Dec 2026 (Q3 FY27). This is critical to margin recovery thesis (cell at 35-41% margin vs 20-25% module-only). Any delay pushes inflection into FY28, prolonging margin pressure.
Inventory & customer offtake risk
MediumQ1 inventory built ahead of expected H2 dispatch. Non-DCR offtake deferred in Q1 due to ALMM-II facility late-coming (Jun 1). If H2 offtake misses, inventory pile-up and margin compression extend into FY28.
Policy dependence
MediumWaaree's FY27 guidance and margin recovery hinge on DCR demand (highest realization tier), ALMM quota compliance, and PLI subsidies (₹1,920 Cr approved). If any withdrawn or significantly watered, revenue visibility and margin erode.
Customer concentration & channel risk
LowTop 5 customers 27.1% (improved from 33% FY26). Top 10 customers 37.1% (improved from 47%). While improving, significant concentration remains. One large customer offtake deferral (e.g., non-DCR segment in Q1) can ripple.
Management
Score 7/10. Transparent on Q1 headwinds (raw material inflation, export delays, inventory build). Detailed margin roadmap (four levers: DCR ramp, U.S. local production, export recovery, non-DCR offtake). Candid on policy dependence. Hedged on segment-specific margins (reasonable given PCM sensitivity). Capex milestones on-time (3 GW module live, 10 GW cell equipment in-house, BESS container live, APS deal closed, 125 MW HJT order). Retail scaling faster than expected (₹2,289 Cr this Q, +130% YoY). Module volumes +89% YoY (though -14% QoQ masks softer near-term). Order book ₹61,500 Cr (highest ever) suggests market confidence in execution.
1 · Q2 FY27 (Aug-Sep)
Cell capacity ramp to 1.2 GW; U.S. export recovery post-tariff lull; non-DCR 6-month offtake window opens
2 · Q3 FY27 (Oct-Dec)
10 GW cell facility comes online (equipment on-site); cell-to-module integration leaps from 20% to 65%; margin inflection
3 · Dec 2026
Non-DCR extension window closes; all offtake must clear by government deadline
But Q1 delivered softer margins (18.1% OPM, PAT +15% vs revenue +79%), module production fell QoQ, and FY27 ₹7,000-7,700 Cr EBITDA guidance reaffirmed (not raised) looks ambitious at current run-rate.
Consolidated PAT ₹892 Cr up 15% but margins compress; underlying flat as a one-off flatters
PAT +15.4% YoY · revenue +79.2% · margins compressing · miss vs street
₹7,931.79 Cr
+79.2% YoY
₹891.87 Cr
+15.4% YoY
11.01%
-5.8pp YoY
₹29.56
Consolidated revenue from operations of ₹7,931.79 Cr rose 79.2% YoY off a ₹4,425.83 Cr year-ago base but slipped 6.5% sequentially from Q4's ₹8,480.25 Cr. Net profit of ₹891.87 Cr (₹850.22 Cr to owners) grew a much slower 15.4% YoY and fell 20.8% QoQ, taking EPS to ₹29.56 from ₹36.91 last quarter. The gap between an ~80% topline and a 15% bottom line is the quarter's story — profit is not scaling with revenue.
Q1 FY-2027 vs prior quarters
Both lines are flattered by a one-off: a ₹349.28 Cr IEEPA reciprocal-duty refund (net of amounts due to customers), recognised as other operating revenue after the US Supreme Court struck down the reciprocal duties, with a ₹282.30 Cr equivalent in the standalone entity. Stripping the ~₹257 Cr post-tax benefit, underlying PAT actually declined ~18% YoY — so the reported +15% is closer to ~-18% adjusted. Net margin compressed to 11.0% (16.8% a year ago, 13.0% last quarter) and operating EBITDA margin to ~18% (22.5% YoY); ex the refund, EBITDA margin is nearer 14%. The squeeze sits in gross margin and realisation as module capacity scales ahead of pricing — the oversupply risk the bears flagged.
The stock went into the print at ₹2,736.2, down 7.2% over the past month of trading.
Management guides for FY27 operating EBITDA of INR 7,000 to INR 7,700 crores, driven by capacity scaling and the execution of its ambitious 'Waaree 2.0' strategy. This involves significant capex in vertical integration (cells, wafers, glass) and diversification into new energy segments like BESS, inverters, and electro
On the Street's own litmus from our pre-result preview — bulls needed EBITDA margins recovering to 21-23% to validate the thesis, a stall below 19% confirming cyclical-peak risk — Q1's ~18% (14% adjusted) lands on the bear side, and Simply Wall St flags an ~10% EPS miss versus consensus; UBS's July 14 downgrade (margin compression, capex execution risk) reads as vindicated on this print. Management's Q4 guidance is unbroken but back-ended: FY27 EBITDA of ₹7,000-7,700 Cr with margins recovering to 19-20% in H2 as 10 GW of new cell capacity comes online. Q1 EBITDA of ~₹1,440 Cr is only ~19-21% of the full-year floor, so FY27 is now entirely an H2 story; management gives no formal quarterly guidance and issued no separate press release with this result.
W1
Margin recovery: management guides EBITDA margin to 19-20% in H2 FY27 as 10 GW cell capacity comes online; Q1 was ~18% (14% ex refund) — verify the H2 uplift
W2
FY27 EBITDA guidance ₹7,000-7,700 Cr; Q1 delivered ~₹1,440 Cr (~19-21% of the floor) — track the back-ended ramp
W3
BESS contribution (facility live July, immaterial to Q1) and CBP/AD-CVD investigation outcome
Order momentum tests execution at scale—watch BESS traction and margin hold
Waaree Energies enters Q1 FY-2027 results (July 29) with a bullish order book: 1,248+ MW of solar module orders booked since June (800 MW + 212 MW + 236 MW to subsidiaries) and India's first automated BESS container facility now live. The Street watches two drivers: (i) revenue scaling on order execution and ASP realization, (ii) BESS business ramp-up—a potentially higher-margin revenue stream that could reshape the earnings mix. Ownership backdrop: promoter holding consolidated via C.T. Doshi Family Trust (44–62% stake transfer, July), FII building from 0.7% (Q4 FY25) to 7.05% (Q4 FY26), and stock trading -27% from ATH at ₹2,702.
The Setup: Order Velocity and Execution at Scale
Waaree Energies is a solar module manufacturer with emerging battery energy storage (BESS) credentials—a pivotal quarter for demonstrating both. In the past six weeks alone, the company has announced 1,248+ MW of solar module orders: the headline 800 MW deal (June 15, valued ~₹2,000+ Cr to a leading energy solutions provider), 212 MW (July 17), and 236.22 MW to its own Americas subsidiary (June 30). This order velocity, if converted at healthy realized prices and margins, would substantially lift Q1 FY-2027 revenue versus run-rate expectations. Parallel to this, Waaree ESS (the company's BESS subsidiary) has commissioned India's first automated Battery Energy Storage System container manufacturing facility (July 16), positioned to serve the growing utility-scale energy storage demand as India's renewable capacity expands. The Street watches Q1 execution tightly: can Waaree convert this order momentum into revenue and margin without working capital strain or factory utilization headwinds? BESS is nascent but signals management's intent to participate in a faster-growing, potentially higher-margin segment.
~₹900–1,100 Cr
On-plan baseline assumes strong order execution from 1,248+ MW visibility. Prior FY26 Q1 not disclosed; judging call on order-to-revenue conversion timing.
~12–16%
ASP realization and manufacturing utilization are swing factors. Large orders may carry pricing pressure vs smaller domestic deals.
Early-stage; likely immaterial to Q1 PAT
Capital spend booked, ramp cost in P&L; watch for path to positive contribution H2 FY27.
What Good vs Weak Looks Like
A strong Q1 print: Revenue in the ₹950–1,100 Cr range, demonstrating execution on announced orders; EBITDA margin 13%+, holding despite volume ramp (showing pricing discipline and cost control); PAT beat expectations by 10%+; management guides full-year FY27 order book and capacity expansion trajectory (BESS factory utilization path). Working capital cycle stable or improving—a critical signal that large order inflow isn't choked by receivables/inventory drag. A weak print: Revenue below ₹900 Cr (order slippage or delayed recognition); EBITDA margin compressed to 10% or below (pricing concessions on bulk deals or factory under-utilization); BESS facility ramp-up costs drag margins sharply; guidance withdrawn or Q2 outlook flagged for further pressure. Management commentary on order book attrition or supply-chain headwinds would be a red flag.
On Track for FY27 Guidance?
Waaree has not announced formal full-year FY27 guidance in recent filings. The company's trajectory is best judged against order book visibility: 1,248+ MW of orders provides strong revenue backlog for the coming quarters, assuming typical 3–4 month order-to-delivery cycles. The BESS facility launch (July 16) is a capital-intensive, long-term bet; near-term Q1 contribution will be negative (capex + ramp-up overhead). Watch for management clarification on FY27 revenue targets, margin guardrails, and BESS path to profitability. Prior management guidance (if any from AGM or prior quarters) is not available in our dataset; the call's credibility will rest on order execution and factory throughput commentary.
Street View & Valuation Debate
Since Last Quarter: Filings & Corporate Activity
1 · Order Inflow (Bullish)
800 MW deal (June 15, ~₹2,000+ Cr), 212 MW (July 17), 236.22 MW to subsidiary (June 30). Largest order intake visible in recent disclosures—suggests strong demand and pricing resilience in utility-scale solar module market.
2 · BESS Facility Launch (Strategic)
Waaree ESS operational at India's first automated BESS container facility (July 16). Near-term margin headwind; longer-term opportunity in 300+ GW renewable energy storage pipeline (per government targets). Watch capex guidance and break-even timeline.
3 · Promoter Restructuring (Neutral)
C.T. Doshi Family Trust acquires 44.14–62.48% stake via gift from Chimanlal Doshi (July 10–23). Internal governance consolidation; no dilution signal. Promoter holding remains stable ~64%.
4 · CPO Resignation (Procedural)
Sanjeev Pushkarna, Chief Procurement Officer, resigned effective June 30, 2026. Impact: likely to be low. Procurement role is operational; no material strategic change flagged in disclosure.
5 · Australian Subsidiary Deregistration (Routine)
Waaree Renewable Energies Australia PTY Limited deregistered by ASIC (June 10, 2026). Wind project exit or low-priority geography. Routine for non-core markets.
6 · US Customs Clearance (Positive)
CBP confirmed Waaree exclusion from EAPA consolidated duty investigation (June 28, 2026). Removes trade friction risk; important for export competitiveness and margins on overseas orders (e.g., Americas subsidiary 236 MW order).
What to Watch on Result Day (July 29)
1 · Q1 Revenue & Order Conversion
The make-or-break: did Waaree recognize revenue from the 1,248+ MW order inflow? At what ASP (Average Selling Price) and margin? Order timing suggests June–July delivery, but some may spill to Q2. Revenue in ₹950–1,100 Cr range would validate execution; anything below ₹850 Cr flags order slippage or recognition timing.
2 · EBITDA Margin & BESS Impact
Watch blended EBITDA margin 12%+. If compressed below 10%, judge whether it's factory ramp-up (transient) or pricing pressure (structural). BESS facility capex and startup costs should be quantified; management's path to 15%+ blended margin by H2 FY27 or FY28 is critical for credibility.
3 · FY27 Guidance & Capex Plan
First guidance of the year. Management should clarify: (a) full-year revenue target and order-book visibility by quarter, (b) BESS capex roadmap and profitability inflection, (c) working capital trajectory (receivables, inventory, payables cycles). Any pullback in guidance or weak H2 FY27 outlook would signal execution risk.
Waaree Energies is testing a pivotal moment: can it scale manufacturing to absorb 1,248+ MW of near-term order inflow while launching BESS as a parallel, higher-margin growth engine? Q1 FY-2027 is the first print to show execution credibility. Revenue in the ₹950–1,100 Cr range with EBITDA margin 12%+ would justify the order book momentum and institutional interest flowing back in (FII 7.05% in Q4 FY26). Margin compression, order slippage, or weak BESS ramp-up commentary would confirm valuation concerns that pushed the stock -27% from ATH. Watch the call for order-to-revenue conversion, margin sustainability, and management's FY27 guidance—those three metrics will define whether this order cycle is a cyclical windfall or the start of a sustained growth leg.
Record orders, margin stumble—the risk is Q1 soft becomes Q2-Q4 softer
Revenue jumped 79% and the order book hit a record ₹61,500 Cr, but profit grew only 15%—and management held guidance rather than raising it. The quarter shows structural strength masked by near-term pressure that has to reverse in the second half.
79.2%
₹7,932 Cr delivered vs prior ₹4,424 Cr
15.4%
₹892 Cr delivered vs prior ₹773 Cr
18.1%
flat YoY, –6 bps QoQ
–20.8%
From ~₹1,126 Cr last quarter
Waaree delivered the headline growth story the street expected—revenue +79% YoY, module volumes +89% to 3.6 GW, order book at an all-time high of ₹61,500 Cr. On the surface, it is a textbook scaling play. But under the surface, the quarter reveals two stories in tension: a structural bull case intact, and a near-term stumble that management is not yet confident can be reversed.
The tension lives in the profit line. Revenue leapt 79%, but profit grew only 15%—a 64-percentage-point gap. That gap is earnings quality compression: raw material cost inflation, inventory build ahead of uncertain offtake, and softer-than-expected margins on the module base. Worse, profit actually fell 20.8% quarter-on-quarter, signaling that the growth narrative is decelerating fast once you strip out the YoY comps.
And the most telling sign: management reaffirmed FY27 operating EBITDA guidance of ₹7,000–7,700 Cr rather than raising it. That is the market's single biggest red flag. A record order book, a retail channel doubling at +130% YoY, and capex execution visible (APS deal closed, BESS live, 10 GW cell equipment in-house)—and yet no guidance bump. It tells you management sees H2 as a prove-it moment, not a coronation.
What the numbers actually say
Highest order book ₹61,500 Cr, up 23% QoQ
Confirmed; 10.2 GW module equivalent with 40% India, 36% U.S., 24% exports—well diversified
Supported
Revenue grew 79.2% YoY to ₹7,932 Cr
Delivered exact ₹7,932 Cr—no miss, no beat; matched guidance
Supported
Operating EBITDA 18.2% margin, up 44% YoY
Delivered 18.1% OPM (marginally lower); margin essentially flat YoY, compressed -6 bps QoQ
Overstated
Module volumes +89% YoY from 1.9 GW to 3.6 GW
YoY growth real, but production fell 14% quarter-on-quarter from 4.2 GW last Q—YoY growth narrative masks deceleration
Slightly overstated
Cell capacity 800 MW this quarter ramping to 1.5 GW by Q3-Q4
Equipment on-site, ALMM-II applied, timeline credible but ambitious; yield/integration risk real
Corroborated but execution-dependent
FY27 EBITDA guidance ₹7,000–7,700 Cr reaffirmed; cell ramp backs recovery
Q1 EBITDA ₹1,440 Cr implies ₹5,560–6,260 Cr needed Q2-Q4 (avg ₹1,853–2,087 Cr/Q). That is 29–45% above Q1 run-rate—doable but demanding
Corroborated but tight on execution
What changed on this call
Retail business inflecting faster than expected. Q1 retail revenue ₹2,289 Cr (+130% YoY vs ₹995 Cr prior year) annualizes to ₹9.2k Cr and sits comfortably inside the ₹9,000–10,000 Cr FY27 target. This is a genuine channel de-risking, reducing dependence on 5–10 large utilities.
Cell integration roadmap crystallizing. 10 GW cell equipment fully on-site, ALMM-II cleared. Cell-to-module integration to jump from 20% (now) to 65% by Q3–Q4. This is the structural margin lever: cell profitability at ₹0.04–0.05/Wp mfg cost but ₹0.12–0.13/Wp DCR market price; margin uplift to 35–41% once integrated vs 20–25% module-only.
U.S. tariff headwinds proved real and exports took the hit. Export revenue fell sharply Q1; management blamed 6-month market lull due to tariff confusion. U.S. order book is 25% of total. Recovery assumed Q2+ but not guaranteed. This is the biggest near-term wildcard.
The bull-bear ledger
Order book at ₹61,500 Cr is all-time high and provides 9–12-month visibility
Capex execution visible: APS 55% stake closed, BESS container live, cell equipment in-house, retail network deepening
Retail revenue doubling (+130% YoY) and moving toward ₹9–10k Cr run-rate de-risks concentration
Cell capacity ramp (5.4 GW → 15.4 GW by year-end) is the core margin lever; roadmap credible
Policy tailwinds real: DCR 100% by FY29, ALMM quota protection, PLI ₹1,920 Cr approved, wafer policy Jun 2028
Structural thesis intact: de-risking via backward integration, supply chain capture, retail, geography
But: PAT grew only 15% while revenue grew 79%—margin compression is severe and real
QoQ PAT fell 20.8% and module production fell 14% QoQ—the growth story is decelerating fast
Guidance reaffirmed not raised—management sees H2 as risky, not a coronation
Inventory build masking offtake risk; if H2 customer deferrals extend, working capital deteriorates
U.S. tariffs real and 6-month lull hit exports; 25% of order book is U.S. sales, vulnerable
Cell capacity ramp by Dec 2026 is ambitious; any yield/integration delay pushes margin inflection into FY28
Raw material cost inflation (polysilicon, glass, silicon) may not reverse quickly; margin recovery dependent on ramp+pricing
Risks, ranked by how much they should concern a holder
Cell capacity ramp and yield: 10 GW equipment online by Dec 2026, but ramping to full production within same quarter is aggressive. Yield issues or integration delays would push margin inflection into FY28.
HighFY27 EBITDA guidance depends on H2 cell contribution. If cell comes online late or yields fall, H2 EBITDA target becomes unachievable and FY28 guidance will need reset downward.
U.S. tariff headwinds persist or widen: 6-month market lull cited; recovery assumed Q2+ but tariff policy may not stabilize. 25% of order book is U.S. sales at ₹0.04–0.05/Wp margin—if tariffs widen further, margin erodes.
HighU.S. local manufacturing (1.6 GW) is the mitigation, but ramp is also dependent on Q2–Q3 execution. Any delay in local capacity or continued tariff uncertainty could force export deferrals into FY28.
Customer offtake timing: Non-DCR 6-month extension window critical; if offtake defers past Dec 2026, inventory pile-up extends working capital drag and margin compression into FY28.
MediumQ1 inventory built ahead of expected H2 dispatch. If H2 offtake misses, inventory will become a cash-flow drag and signal weakening customer confidence.
Policy withdrawal: ALMM/PLI/DCR removal or watering would crater realization tiers (₹0.12–0.13/Wp DCR vs $0.04–0.045 import). Structural but not guaranteed long-term.
MediumManagement argues policies are structural (like defence, electronics), but political risk is real. Any withdrawal would reset the margin thesis and force pricing power downward.
Capex execution: ₹31,500 Cr over 3 years across 6 business units (module, cell, wafer, T&D, BESS, inverter). Any single delay cascades; ROCE-accretion claims unproven.
MediumCapital intensity is high; if ROCE on capex falls below 12–15%, return on equity will deteriorate and funding needs (₹10k Cr QIP planned) will increase.
How the street is positioned
Price action is the market's own verdict: the stock fell 4.07% on day 1 post-result announcement (Jul 29) and has not recovered. It trades at ₹2,660.9 as of Aug 6, down 28.45% from its all-time high and below all key moving averages (SMA20 ₹2,748, SMA50 ₹2,902, SMA200 ₹3,019). The sell-off is telling: the record order book and capex execution were not enough to offset the margin miss and guidance hold.
Ownership tells a different story: FII have quietly been adding (7.05% in Q4 FY26 vs 0.70% in Q1 FY25—a 10x increase), suggesting institutional confidence in the structural bull case. But DII remain light (4.32%), and the lack of domestic institutional support is a yellow flag. Promoter ownership stable at 64.19%, so no insider selling pressure. The FII accumulation suggests long-term investors believe in the Waaree 2.0 thesis, but the DII silence and stock weakness suggest they are waiting for proof of H2 execution before adding.
Valuation compression is real: down 28% from ATH and trading below all SMAs, the stock has priced in execution risk. At current levels, if H2 cell ramp and offtake recovery materializes, the upside is significant (back to ATH, another 40%). If H2 disappoints, the downside is also significant (another 15–20% to test support below current lows). This is a binary setup: prove-it quarter.
What to watch next
1 · Cell capacity ramp: 800 MW → 1.2 GW by Q2-Q4
Cell production ramping is the core margin lever. Track quarterly cell volumes and yields; if they track guidance, margin recovery is credible. If they miss, FY27 EBITDA target is at risk.
2 · Module production stabilization and H2 offtake recovery
Module production fell 14% QoQ to 3.6 GW. Q2-Q4 should show a recovery to 4+ GW/Q as non-DCR offtake window opens (6-month extension through Dec). If production remains flat or falls further, it signals customer deferrals are extending into H2.
3 · Operating margin inflection: watch for 18.5%+ by Q3-Q4
Q1 OPM was 18.1%, flat YoY and -6 bps QoQ. Management guides for margin recovery in H2 via cell integration and capacity utilization. If Q2-Q3 OPM remains below 18%, cell ramp is not delivering margin accretion and the H2 recovery thesis is broken.
The honest read
Waaree's Q1 FY27 was a tale of two tensions: headline growth (+79% revenue, record order book) vs. near-term stumble (PAT +15%, QoQ PAT -20.8%, margin flat YoY, module production down QoQ, guidance held). The stock has repriced from ATH ₹3,718 to ₹2,661 (down 28%), and the street is split between long-term believers (FII 7.05%, quietly accumulating) and cautious near-term traders (DII light, stock below all SMAs).
The bull thesis—structural de-risking via cell integration, capex execution, retail ramp, and policy tailwinds—is intact and real. But it is now a hostage to H2 delivery. Management has one quarter to prove cell ramp (800 MW → 1.5 GW), module recovery (3.6 GW → 4+ GW/Q), and margin inflection (18.1% → 18.5%+) are achievable. If they are, the upside to ₹3,500+ is substantial. If they are not, the downside to ₹2,200 is also substantial. Until then, execution risk warrants a Hold.